Search

The objective of this study was to compare the effects of &gt, Your&lt, Iron Syrup, a novel oral liquid iron-containing food supplement, with the commonly prescribed iron sulphate (Fe-sulphate) in a mouse model of diet-induced iron deficiency. Standard inbred BALB/cOlaHsd mice were fed low-iron diet for 11 weeks to induce significant decrease in blood haemoglobin and haematocrit and were then supplemented by gavage with either &gt, Iron Syrup or Fe-sulphate for two weeks. In &gt, Iron Syrup group, several markers of iron deficiency, such as serum iron concentration, transferrin saturation and ferritin level were significantly improved in both female and male mice. Fe-sulphate induced similar responses, except that it did not significantly increase iron serum in females and serum ferritin in both sexes. Fe-sulphate significantly increased liver-iron content which &gt, Iron Syrup did not. Transcription of Hamp and selected inflammatory genes in the liver was comparable between the two supplementation groups and with the Control diet group. Some sex-specific effects were noted, which were more pronounced and less variable in males. In conclusion, &gt, Iron Syrup was efficient, comparable and in some parameters superior to Fe-sulphate in improving iron-related parameters without inducing a response of selected liver inflammation markers in a mouse model of diet-induced iron deficiency.

Additional file 1: Table S1. Baseline demographic characteristics of canine DCM and MMVD patients and control dogs. Table S2. Inflammatory markers (Median, IQR) and NT-proBNP concentrations (Median, IQR) in DCM and MMVD patients and control dogs. Table S3. Oxidative stress markers (mean ± SD) in DCM and MMVD patients and control dogs.

Additional file 1. Procedures for the multivariate models.

The aim of the present study was to investigate the effect of meloxicam and meloxicam with misoprostol on prostaglandin E2 (PGE2) and prostaglandin I2 (PGI2) serum concentration, as well as on gastrointestinal permeability. NSAIDs, such as meloxicam, have gastrointestinal side effects, which are due to prostaglandins depletion and topical damage. Seven adult beagle dogs were included in the study. Three different 20 days long treatments were carried out (placebo, meloxicam and meloxicam with misoprostol). The same seven dogs participated in all three treatments. On days 1 to 10 the dogs received placebo, meloxicam or meloxicam together with misoprostol PO. Dogs were than monitored from day 11 to 20. Samples for serum PGE2 and PGI2 concentration and plasma lactulose, mannitol and sucrose concentration determination were drawn on day 0, 2, 6, 11 and 20. Lactulose/mannitol (L/M) index was calculated. Treatment with meloxicam and meloxicam with misoprostol resulted in lower PGE2 and PGI2 serum concentrations in comparison to the placebo. L/M index and sucrose plasma concentration were increased in both groups in comparison to the placebo. According to the results of the study, meloxicam has altered gastrointestinal permeability and depleted prostaglandins production. Misoprostol was shown to be an effective preventing treatment.